Nota de idioma: o chrome desta página está em português; o corpo longo abaixo permanece em inglês para preservar a precisão das fontes.
Liraglutide
Also indexed as Victoza · Saxenda · GLP-1 receptor agonist
Liraglutide is an earlier long-acting GLP-1 receptor agonist in the same broad class as semaglutide. It has approved product histories in diabetes and weight management, each with its own label.
Last reviewed 2026-09-07 · education only
O que aparece na literatura
It activates the GLP-1 receptor and participates in glucose-dependent insulin signaling and appetite biology. The mechanism is a pharmacology map, not a treatment plan.
History & development
- 2008
Novo Nordisk's heritage timeline places liraglutide GLP-1 research in the company's development history.
Source: Novo Nordisk heritage ↗
- 2010
Victoza entered the approved product record for type 2 diabetes in the United States; consult the current label for status and indications.
Source: DailyMed: Victoza label ↗
- 2014
Saxenda established a separate liraglutide product and weight-management label in the United States.
Source: DailyMed: Saxenda label ↗
Approved brands & pathway
Victoza
United StatesFDA-approved prescription product
Liraglutide product with a diabetes label; read the current label.
Open DailyMed label search ↗Saxenda
United StatesFDA-approved prescription product
Liraglutide product with a weight-management label; read the current label.
Open DailyMed label search ↗Entradas de evidência
Tema: Obesity · GLP-1 · Categoria: Obesity
Liraglutide
O que a fonte sustenta
Randomized clinical weight-loss research
SCALE Obesity and Prediabetes assessed liraglutide with lifestyle intervention over 56 weeks in adults with obesity or overweight and comorbidity.
Limite: The trial used a regulated product, eligibility criteria and monitored protocol; it cannot validate another source or route.
Fonte: SCALE · NEJM Ler fonte ↗
Tema: Obesity · comparator literacy · Categoria: Obesity
Semaglutide vs liraglutide
O que a fonte sustenta
Randomized head-to-head clinical research
STEP 8 compared once-weekly semaglutide with daily liraglutide and placebo in adults with overweight or obesity under a defined protocol.
Limite: Head-to-head results still depend on the study population, regimen, adherence and approved clinical context.
Fonte: STEP 8 · NEJM Ler fonte ↗
Grade mix in this atlas
Grades describe the cited record for a narrow question. They do not score a marketplace material or make a health decision.
Naming curiosities & useful distinctions
- Victoza and Saxenda contain liraglutide, but the product names do not erase the label differences.
- Liraglutide is a useful comparator in STEP 8, a published head-to-head study with semaglutide.
The older comparator
The SCALE program and STEP 8 give liraglutide a visible place in the modern GLP-1 evidence map, while the approved-label context remains the anchor.
Nomes no registro
Developer
Novo Nordisk
Company history documents liraglutide within its GLP-1 development program.